Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Glioblastoma 69Glioma 26Brain Neoplasms 26Gliosarcoma 23Melanoma 17Central Nervous System Neoplasms 14Astrocytoma 12Neuroblastoma 10Rhabdomyosarcoma 8Small Cell Lung Carcinoma 6Sarcoma, Ewing 6Neoplasms 6Neoplasm Metastasis 6Medulloblastoma 6Recurrence 5Sarcoma 4Ovarian Neoplasms 4Osteosarcoma 4Oligodendroglioma 4Wilms Tumor 3Prostatic Neoplasms 3Neuroectodermal Tumors, Primitive, Peripheral 3Ependymoma 3Diffuse Intrinsic Pontine Glioma 3Breast Neoplasms 3Rhabdoid Tumor 2Pancreatic Neoplasms 2Optic Nerve Glioma 2Lymphoma, Follicular 2Lymphoma 2

Interventions

Cetuximab 44Oxaliplatin 39Irinotecan 38Fluorouracil 36Capecitabine 36pembrolizumab 35Leucovorin 35Bevacizumab 35Nivolumab 21Gemcitabine 17regorafenib 13Panitumumab 12IFL protocol 12Folfox protocol 12Cyclophosphamide 12Pemetrexed 11Cisplatin 11tislelizumab 9Paclitaxel 9HMPL-013 9Carboplatin 9130-nm albumin-bound paclitaxel 8durvalumab 7Specimen Handling 7Docetaxel 7trametinib 6Trifluridine 6Ipilimumab 6Drug Therapy 6trifluridine tipiracil drug combination 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Colorectal Neoplasms × Temozolomide × Clear all
NCT05691491 2026-05-13

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

National Cancer Institute (NCI)

Phase 1/2 Recruiting
58 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT04689347 2026-01-12

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 1/2 Recruiting
27 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡